Fig. 5

Cancer type-specific correlation of ELF3 with patient survival. A Higher ELF3 levels correlate with worse patient outcomes in breast cancer samples (i) overall survival (GSE3494), ii) relapse-free survival (GSE4922), and iii) metastasis-free survival (GSE48408) B In colorectal cancer samples, lower ELF3 levels correlate with worse patient outcomes: i) overall survival (GSE16125), ii) relapse-free survival (GSE28814), and iii) metastasis-free survival (GSE28814), showing lower. C i) A gene regulatory network coupling ELF3 with the EMT core network (miR-200, ZEB1, SLUG) and Estrogen Receptor isoforms (ERα66, ERα36) in the context of ER + breast cancer. Red hammers represent inhibitory links and green arrows represent activation links; ii) Heatmap of steady state solutions upon simulation of the GRN in i); iii) Percentage of steady state solutions resulting in each of the phenotype pairs: Epithelial and Resistant (Epi-Res), Epithelial and Sensitive (Epi-Sen), Hybrid and Resistant (Hyb-Res), Hybrid and Sensitive (Hyb-Sen), and Mesenchymal and Resistant (Mes-Res) in control, 20-fold up or downregulation of ELF3; * represents a statistically significant difference in the fraction of cases that end up in the epithelial phenotype (Students t-test; p-val < 0.05)